US biopharma Kymera Therapeutics (Nasdaq: KYMR), which is developing a new class of small molecule medicines using targeted protein degradation (TPD), has announced an important update on its pipeline.
The company is to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance the cancer candidates KT-333 (STAT3) and KT-253 (MDM2) beyond Phase I with a partner.
Nello Mainolfi, founder, president and chief executive, Kymera, said that it had been an important year for Kymera.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze